Effect of neoadjuvant chemotherapy on [68Ga]Ga-FAPI-46 PET/CT in peritoneal carcinomatosis: a prospective translational exploratory sub-cohort analysis
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8116-8128
DOI: 10.1007/s00259-026-08114-8 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 01.08.2026. Verfasst von Ayça Arçay Öztürk und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, Brusse…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Neoadjuvant Therapy, Peritoneal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: L'Association Jules Bordet.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
To evaluate whether [^68Ga]Ga-FAPI-46 PET/CT (FAPI PET) is sensitive to neoadjuvant chemotherapy (NAC)-associated changes in peritoneal carcinomatosis (PC) and whether post-NAC FAPI PET parameters and pre-/post-NAC changes are associated with histopathologic and biochemical response.
Methods
This exploratory translational sub-cohort analysis was conducted within the prospective phase II FAPeCa trial (NCT06061874) recruiting patients with colorectal or ovarian cancer with known/suspected PC. Patients who received recent chemotherapy were included in the current analysis. PET parameters, including SUVmax, peritoneal tumour volume (PTV), and total lesion uptake (TLF/TLG) were analysed both on FAPI and [^18F]-FDG PET/CT. Associations with pathological chemotherapy response score (pCRS) and CA-125 change were explored. Pre- and post-NAC paired FAPI PET and FAP immunohistochemical (IHC) analyses were performed. Segment-level correlation between IHC score and FAPI PET uptake was assessed.
Results
Twenty-seven patients were included, predominantly with ovarian cancer (26/27), including 10 with paired pre-/post-NAC imaging. All paired FAPI PET parameters declined significantly after NAC. The magnitude of change in paired FAPI PET parameters correlated strongly with pCRS, particularly for SUVmax (ρ=0.866, p=0.005), PTV(2.5) (ρ=0.830, p=0.011), and TLF(2.5) (ρ=0.830, p=0.011), whereas FDG PET parameters and FAPI PTV(40) and TLF(40) showed no significant correlation with pCRS. Changes in FAPI PET parameters also correlated with the CA-125 change. Across the post-NAC cohort, FAPI PET volumetric parameters differed significantly across pCRS categories. Paired IHC demonstrated a significant reduction in FAP expression after NAC, and segment-level FAP IHC score showed a significant moderate correlation with FAPI uptake (SUVmax ρ=0.467, p=0.012; SUVmean ρ=0.554, p=0.005). Conclusions: [^68Ga]Ga-FAPI-46 PET/CT demonstrated treatment sensitivity after NAC in PC, with concordant reductions in PET parameters and stromal FAP expression. FAPI PET volumetric parameters were associated with histopathologic response and CA-125 change in this exploratory sub-cohort, supporting further investigation of FAPI PET as an imaging biomarker for response assessment in PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, Brussels, 1070, Belgium. ayca.arcayozturk@hubruxelles.be.
- Department of Digestive Surgery and Digestive Surgical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
- Department of Pathology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
- ATheNO Laboratory, Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
- Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, Brussels, 1070, Belgium.
- Department of Medical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Förderung
- L'Association Jules Bordet
Zitieren
APA
Arçay Öztürk, A., Liberale, G., Noël, J. C., Delbart, W., Deleu, A. L., Woff, E., Poenaru, R., Polastro, L., Theunissen, L., Kristanto, P., Vercauteren, S., Marin, C., Taraji, L., & Flamen, P. (2026). Effect of neoadjuvant chemotherapy on [68Ga]Ga-FAPI-46 PET/CT in peritoneal carcinomatosis: a prospective translational exploratory sub-cohort analysis. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8116-8128. https://doi.org/10.1007/s00259-026-08114-8
Vancouver
Arçay Öztürk A, Liberale G, Noël JC, Delbart W, Deleu AL, Woff E, et al. Effect of neoadjuvant chemotherapy on [68Ga]Ga-FAPI-46 PET/CT in peritoneal carcinomatosis: a prospective translational exploratory sub-cohort analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8116-8128. doi:10.1007/s00259-026-08114-8
BibTeX
@article{Arayztrk2026,
author = {Arçay Öztürk, Ayça and Liberale, Gabriel and Noël, Jean Christophe and Delbart, Wendy and Deleu, Anne-Leen and Woff, Erwin and Poenaru, Raluca and Polastro, Laura and Theunissen, Laurent and Kristanto, Paulus and Vercauteren, Sigrid and Marin, Clementine and Taraji, Loubna and Flamen, Patrick},
title = {Effect of neoadjuvant chemotherapy on [68Ga]Ga-FAPI-46 PET/CT in peritoneal carcinomatosis: a prospective translational exploratory sub-cohort analysis},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8116--8128},
doi = {10.1007/s00259-026-08114-8}
}
EUVIMED